Authors: Zhang, N.; Bertera, S.; Qu, S.; He, J.; Su, D.; Bottino, R.; Bromberg, J.; Dong, H. H.

Source: Immunology Endocrine & Metabolic Agents - Medicinal Chemistry (Formerly Current Medicinal Chemistry - Immunology Endocrine & Metabolic Agents), Volume 6, Number 2, April 2006 , pp. 155-166(12)

Publisher: Bentham Science Publishers

Abstract:

Successful islet transplantation depends on the infusion of sufficiently large quantities of islets, requiring multiple pancreas donors per recipient. Unfortunately, more than 70% of functional islet mass are lost in the early posttransplantation phase. Unlike whole-organ transplantation by which grafts are implanted as vascularized tissue, islets are transplanted as single islets or islet clusters that are considered avascular. As a result, microvascular perfusion to newly transplanted islets does not resume immediately after transplantation and can take up to weeks until the reestablishment of a functional microvasculature within islet grafts. Delayed and insufficient islet revascularization can deprive newly transplanted islets of oxygen and nutrients, resulting in islet cell death and contributing to early graft failure. There is mounting evidence that impaired islet revascularization constitutes an independent factor that reduces the viability and compromises the function of transplanted islets, thereby limiting the success rate of islet transplantation. In this article, we will review the most recent advances made in deciphering the underlying mechanism of islet revascularization and exploring therapeutic strategies for enhancing islet revascularization and preserving functional islet mass in diabetic recipients.

Keywords: Islet transplantation; islet revascularization; angiogenesis; type 1 diabetes

Document Type: Research article

DOI: http://dx.doi.org/10.2174/187152206776359939

Affiliations: 1: Rangos Research Center, Children's Hospital of Pittsburgh, 3460 Fifth Avenue, Rm 6130, Pittsburgh, PA 15213, USA.

Publication date: 2006-04-01

More about this publication?

• Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry aims to cover all the latest and outstanding developments in the medicinal chemistry and rational drug design for the discovery of new Immunology, Endocrine & Metabolic Agents. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of current topics in Immunology, Endocrine & Metabolic medicinal chemistry.
  
  Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments in Immunology, Endocrine & Metabolic drug discovery.

Related content

• In this: publication
• By this: publisher
• In this Subject: Chemistry ,  Allergy & Immunology ,  Pharmacology
• By this author: Zhang, N. ;  Bertera, S. ;  Qu, S. ;  He, J. ;  Su, D. ;  Bottino, R. ;  Bromberg, J. ;  Dong, H. H.

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers